Mark K. Bennett

20.8k total citations · 9 hit papers
175 papers, 16.1k citations indexed

About

Mark K. Bennett is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Mark K. Bennett has authored 175 papers receiving a total of 16.1k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Molecular Biology, 38 papers in Cell Biology and 36 papers in Oncology. Recurrent topics in Mark K. Bennett's work include Cellular transport and secretion (32 papers), Ubiquitin and proteasome pathways (29 papers) and Multiple Myeloma Research and Treatments (21 papers). Mark K. Bennett is often cited by papers focused on Cellular transport and secretion (32 papers), Ubiquitin and proteasome pathways (29 papers) and Multiple Myeloma Research and Treatments (21 papers). Mark K. Bennett collaborates with scholars based in United Kingdom, United States and Canada. Mark K. Bennett's co-authors include Richard H. Scheller, Nicole Calakos, Mary B. Kennedy, Sidney W. Whiteheart, Thomas Söllner, James E. Rothman, Ngozi Erondu, Alastair D. Burt, Oliver James and Susan D. Demo and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Mark K. Bennett

170 papers receiving 15.7k citations

Hit Papers

A protein assembly-disassembly pathway in vitro that may ... 1983 2026 1997 2011 1993 1992 2014 1995 2007 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion
    1993 1.6k citations Mark K. Bennett et al. profile →
  2. Syntaxin: A Synaptic Protein Implicated in Docking of Synaptic Vesicles at Presynaptic Active Zones
    1992 1.1k citations Mark K. Bennett et al. profile →
  3. Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
    2014 797 citations Matt I. Gross, Susan D. Demo et al. Molecular Cancer Therapeutics profile →
  4. The natural history of nonalcoholic fatty liver: A follow-up study
    1995 734 citations Oliver James, Alastair D. Burt et al. profile →
  5. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
    2007 591 citations Deborah J. Kuhn, Qing Chen et al. Blood profile →
  6. The syntaxin family of vesicular transport receptors
    1993 582 citations Mark K. Bennett et al. profile →
  7. Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
    2007 542 citations Susan D. Demo, Christopher J. Kirk et al. Cancer Research profile →
  8. The molecular machinery for secretion is conserved from yeast to neurons.
    1993 529 citations Mark K. Bennett et al. profile →
  9. Biochemical and immunochemical evidence that the "major postsynaptic density protein" is a subunit of a calmodulin-dependent protein kinase.
    1983 494 citations Mark K. Bennett et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark K. Bennett United Kingdom 53 10.3k 6.6k 2.6k 2.0k 1.7k 175 16.1k
Naoki Mochizuki Japan 64 10.4k 1.0× 4.5k 0.7× 1.9k 0.7× 1.5k 0.7× 661 0.4× 250 17.0k
Tadaomi Takenawa Japan 72 11.4k 1.1× 10.6k 1.6× 1.7k 0.6× 1.0k 0.5× 509 0.3× 237 19.3k
Peter J. Parker United Kingdom 95 25.3k 2.5× 7.6k 1.1× 3.0k 1.2× 1.5k 0.8× 1.3k 0.7× 406 33.7k
Richard A. Cerione United States 86 18.1k 1.8× 6.2k 0.9× 2.2k 0.8× 711 0.4× 996 0.6× 311 24.1k
Alex Toker United States 73 15.1k 1.5× 3.7k 0.6× 940 0.4× 1.2k 0.6× 943 0.5× 136 20.5k
Yi Zheng United States 83 14.1k 1.4× 6.2k 0.9× 1.4k 0.5× 928 0.5× 621 0.4× 364 21.5k
Patrick J. Casey United States 74 14.8k 1.4× 3.5k 0.5× 1.8k 0.7× 1.4k 0.7× 612 0.4× 247 19.3k
Ron R. Kopito United States 67 14.6k 1.4× 7.3k 1.1× 3.9k 1.5× 1.0k 0.5× 4.0k 2.3× 136 22.6k
Jonathan Backer United States 71 12.6k 1.2× 4.8k 0.7× 728 0.3× 2.4k 1.2× 2.1k 1.2× 147 17.4k
Frank Baas Netherlands 79 9.4k 0.9× 2.0k 0.3× 3.9k 1.5× 1.7k 0.9× 1.8k 1.0× 361 21.7k

Countries citing papers authored by Mark K. Bennett

Since Specialization
Citations

This map shows the geographic impact of Mark K. Bennett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark K. Bennett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark K. Bennett more than expected).

Fields of papers citing papers by Mark K. Bennett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark K. Bennett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark K. Bennett. The network helps show where Mark K. Bennett may publish in the future.

Co-authorship network of co-authors of Mark K. Bennett

This figure shows the co-authorship network connecting the top 25 collaborators of Mark K. Bennett. A scholar is included among the top collaborators of Mark K. Bennett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark K. Bennett. Mark K. Bennett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rainham, Daniel, Mark K. Bennett, Christopher M. Blanchard, et al.. (2022). Parents and Children Should Be More Active Together to Address Physical Inactivity and Sedentary Behaviours. Frontiers in Public Health. 10. 633111–633111. 7 indexed citations
2.
3.
Yu, Shirong, Katie Evans, Mark K. Bennett, et al.. (2016). Global genome nucleotide excision repair is organized into domains that promote efficient DNA repair in chromatin. Genome Research. 26(10). 1376–1387. 24 indexed citations
4.
Phillips, Scott, Joel D. Blomquist, Mark K. Bennett, et al.. (2015). U.S. Geological Survey Chesapeake science strategy, 2015-2025—Informing ecosystem management of America’s largest estuary. Antarctica A Keystone in a Changing World. 2 indexed citations
5.
Meric‐Bernstam, Funda, Angela DeMichele, Melinda L. Telli, et al.. (2015). Abstract C49: Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with refractory solid tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). C49–C49. 4 indexed citations
6.
MacKinnon, Andrew L., Mark K. Bennett, Matt Gross, et al.. (2015). Metabolomic, Proteomic and Genomic Profiling Identifies Biomarakers of Sensitivity to Glutaminase Inhibitor CB-839 in Multiple Myeloma. Blood. 126(23). 1802–1802. 4 indexed citations
7.
Gross, Matt I., Susan D. Demo, Jennifer B. Dennison, et al.. (2014). Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 13(4). 890–901. 797 indexed citations breakdown →
8.
Arastu‐Kapur, Shirin, Janet L. Anderl, Marianne Kraus, et al.. (2011). Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events. Clinical Cancer Research. 17(9). 2734–2743. 329 indexed citations
9.
Vij, Ravi, Lühua Wang, Robert Z. Orlowski, et al.. (2009). Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.. Blood. 114(22). 430–430. 13 indexed citations
10.
Demo, Susan D., Christopher J. Kirk, Monette Aujay, et al.. (2007). Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome. Cancer Research. 67(13). 6383–6391. 542 indexed citations breakdown →
11.
Kuhn, Deborah J., Qing Chen, Peter M. Voorhees, et al.. (2007). Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 110(9). 3281–3290. 591 indexed citations breakdown →
12.
Zhao, H., Peter C. Chu, Jianing Huang, et al.. (2005). A Novel E3 Ubiquitin Ligase TRAC-1 Positively Regulates T Cell Activation. The Journal of Immunology. 174(9). 5288–5297. 49 indexed citations
13.
Shuttleworth, James, et al.. (2003). Colour texture analysis using co-occurrence matrices for classification of colon cancer images. 1134–1139. 18 indexed citations
14.
Esgiar, Abdelrahim Nasser, R.N.G. Naguib, Mark K. Bennett, & Alan Murray. (1998). Automated feature extraction and identification of colon carcinoma.. PubMed. 20(4). 297–301. 25 indexed citations
15.
Poirier, Michelle A., Joe C. Hao, Per Malkus, et al.. (1998). Protease Resistance of Syntaxin·SNAP-25·VAMP Complexes. Journal of Biological Chemistry. 273(18). 11370–11377. 109 indexed citations
16.
Bennett, Mark K., et al.. (1996). Age and Embarrassment at Others' Gaffes. The Journal of Social Psychology. 136(1). 113–115. 3 indexed citations
17.
Collier, Jane, Joseph Mathew, Felicity E. B. May, et al.. (1992). c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. Journal of Hepatology. 14(2-3). 377–380. 42 indexed citations
18.
Floreani, Annarosa, Mark K. Bennett, Harriet Mitchison, et al.. (1989). Progression of Autoimmune Damage in Primary Biliary Cirrhosis: An Immunohistochemical Study. Autoimmunity. 2(4). 311–321. 8 indexed citations
19.
Woodhouse, K. W., et al.. (1986). Dextropropoxyphene induced hepatotoxicity mimicking biliary tract disease.. Gut. 27(4). 444–449. 8 indexed citations
20.
Buamah, P K, Peter McArdle, Mark K. Bennett, Oliver James, & R Lendrum. (1986). A pleomorphic hepatocellular carcinoma with biochemical features of fibrolamellar hepatocellular carcinoma. Journal of Surgical Oncology. 32(2). 93–95. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoki Mochizuki Breakdown of academic impact, for papers by Tadaomi Takenawa Breakdown of academic impact, for papers by Peter J. Parker Breakdown of academic impact, for papers by Richard A. Cerione Breakdown of academic impact, for papers by Alex Toker Breakdown of academic impact, for papers by Yi Zheng Breakdown of academic impact, for papers by Patrick J. Casey Breakdown of academic impact, for papers by Ron R. Kopito Breakdown of academic impact, for papers by Jonathan Backer Breakdown of academic impact, for papers by Frank Baas
Rankless by CCL
2026